Last reviewed · How we verify
NCT07530263: NIMBUS
Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA)
Phase 1 trial testing 12 mg of nebulised 99mTc-liposomal amphotericin B in Chronic Pulmonary Aspergillosis in 18 participants. Not yet recruiting.
1 May 2027
Quick facts
| Lead sponsor | Radboud University Medical Center |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 1 May 2026 |
| Primary completion | 1 May 2027 |
| Estimated completion | 1 June 2027 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- 12 mg of nebulised 99mTc-liposomal amphotericin B
- 24 mg of nebulised 99mTc-liposomal amphotericin B
- SPECT/CT scan
Conditions studied
- Chronic Pulmonary Aspergillosis — all drugs for Chronic Pulmonary Aspergillosis →
Sponsor
Radboud University Medical Center
Who can join
18 and older, any sex, with Chronic Pulmonary Aspergillosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates and aims to optimize inhalation treatment with nebulized liposomal amphotericin B in patients with chronic pulmonary aspergillosis. The primary objective is to assess the pulmonary deposition and intrapulmonary distribution of liposomal amphotericin B after nebulization, using technetium-99m-labeled liposomal amphotericin B and SPECT/CT imaging. The study also aims to generate data to inform optimization of inhalation treatment design. Participants will receive two different doses of nebulized liposomal amphotericin B (12 mg and 24 mg) on separate study days. After each administration, participants will undergo SPECT/CT imaging to assess pulmonary deposition. Blood samples will be collected on both study days and after study treatment to evaluate safety and measure systemic amphotericin B concentrations. Participants will also perform spirometry using a handheld device and complete a treatment satisfaction questionnaire on both study days.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07530263
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Pulmonary Aspergillosis
Currently open trials in the same condition.
- NCT06794554 — Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options · Phase 2 · recruiting
- NCT06244979 — iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine · Phase 2 · recruiting
- NCT06885905 — Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-being · recruiting
- NCT06447402 — A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonar · Phase 3 · recruiting
- NCT05444946 — Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome · NA · recruiting
Other Radboud University Medical Center trials
Trials by the same sponsor.
- NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
- NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
- NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
- NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting
- NCT07230028 — Doxycycline Boosted Therapy in Lyme Borreliosis: DoBo Study. · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07530263 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
- Last refreshed: 15 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07530263.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing